Literature DB >> 11465395

Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups.

F G Davis1, V Kupelian, S Freels, B McCarthy, T Surawicz.   

Abstract

Prevalence rates are used to supplement descriptions of disease and are unavailable for all primary brain tumors in the United States. Data from two population-based tumor registries were obtained from the Central Brain Tumor Registry of the United States and used to compute age-specific incidence rates (1985-1994) and survival curves for further use in a statistical model to estimate prevalence rates. Prevalence rates were then used to estimate the number of individuals living with a brain tumor diagnosis in the U.S. population for the year 2000. The overall incidence rate in these regions is 13.8 per 100,000 with 2-, 5-, and 10-year survival rates of 58%, 49%, and 38%, respectively. The prevalence rate for all primary brain tumors is 130.8 per 100,000 with approximately 350,000 individuals estimated to be living with this diagnosis in the United States in 2000. The prevalence rate for malignant tumors, 29.5 per 100,000, is similar to previous reports. The prevalence rate for benign tumors, 97.5 per 100,000, is new. Unlike incidence data, the proportion (and expected number) of existing benign tumors (75%, 267,000) is considerably greater than that for malignant tumors (23%, 81,000), reflecting the better prognosis of benign tumors diagnosed in individuals younger than 60 years old. These data underscore the impact of primary brain tumors in the U.S. health care system and emphasize the need for quality-of-life considerations, particularly for those long-term survivors of benign tumors.

Entities:  

Mesh:

Year:  2001        PMID: 11465395      PMCID: PMC1920611          DOI: 10.1093/neuonc/3.3.152

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  54 in total

Review 1.  Incidental findings found in "healthy" volunteers during imaging performed for research: current legal and ethical implications.

Authors:  T C Booth; A Jackson; J M Wardlaw; S A Taylor; A D Waldman
Journal:  Br J Radiol       Date:  2010-03-24       Impact factor: 3.039

2.  Care and support needs of patients and carers early post-discharge following treatment for non-malignant brain tumour: establishing a new reality.

Authors:  Petrea Cornwell; Bronwyn Dicks; Jennifer Fleming; Terry P Haines; Sarah Olson
Journal:  Support Care Cancer       Date:  2012-10       Impact factor: 3.603

3.  The risks and benefits of searching for incidental findings in MRI research scans.

Authors:  Jason M Royal; Bradley S Peterson
Journal:  J Law Med Ethics       Date:  2008       Impact factor: 1.718

4.  Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas.

Authors:  Sergei I Bannykh; C Claus Stolt; Jung Kim; Arie Perry; Michael Wegner
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

5.  Manipulation of olfactory tight junctions using papaverine to enhance intranasal delivery of gemcitabine to the brain.

Authors:  Mansi Krishan; Gary A Gudelsky; Pankaj B Desai; Mary Beth Genter
Journal:  Drug Deliv       Date:  2013-10-14       Impact factor: 6.419

6.  Caring for the brain tumor patient: family caregiver burden and unmet needs.

Authors:  Jane R Schubart; Mable B Kinzie; Elana Farace
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

7.  A heritable predisposition to pituitary tumors.

Authors:  William T Couldwell; Lisa Cannon-Albright
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

8.  De novo induction of genetically engineered brain tumors in mice using plasmid DNA.

Authors:  Stephen M Wiesner; Stacy A Decker; Jon D Larson; Katya Ericson; Colleen Forster; Jose L Gallardo; Chunmei Long; Zachary L Demorest; Edward A Zamora; Walter C Low; Karen SantaCruz; David A Largaespada; John R Ohlfest
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

Review 9.  Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways.

Authors:  Rosaria Viola Abbritti; Francesca Polito; Maria Cucinotta; Claudio Lo Giudice; Maria Caffo; Chiara Tomasello; Antonino Germanò; Mohammed Aguennouz
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

10.  Descriptive epidemiology of malignant and nonmalignant primary spinal cord, spinal meninges, and cauda equina tumors, United States, 2004-2007.

Authors:  Linh M Duong; Bridget J McCarthy; Roger E McLendon; Therese A Dolecek; Carol Kruchko; Lynda L Douglas; Umed A Ajani
Journal:  Cancer       Date:  2012-01-03       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.